{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.93","upperLimit":"17.23","value":"12.0"},{"groupId":"OG001","lowerLimit":"7.69","upperLimit":"17.00","value":"11.8"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.38","upperLimit":"59.35","value":"52.4"},{"groupId":"OG001","lowerLimit":"47.80","upperLimit":"61.86","value":"54.9"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.36","upperLimit":"15.02","value":"10.1"},{"groupId":"OG001","lowerLimit":"7.69","upperLimit":"17.00","value":"11.8"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.75","upperLimit":"15.58","value":"10.6"},{"groupId":"OG001","lowerLimit":"5.31","upperLimit":"13.59","value":"8.8"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.07","upperLimit":"6.17","value":"2.9"},{"groupId":"OG001","lowerLimit":"0.54","upperLimit":"4.94","value":"2.0"}]}],"title":"Unable to Evaluate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.93","upperLimit":"17.23","value":"12.0"},{"groupId":"OG001","lowerLimit":"6.88","upperLimit":"15.87","value":"10.8"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \\& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan \\& no new sites; no increase in size of other nodes, liver or spleen; with exception of splenic \\& hepatic nodules, involvement of other organs is usually assessable \\& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \\>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or size of other lesions (e.g., splenic/hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who had reached the end of induction treatment response assessment.","reportingStatus":"POSTED","timeFrame":"Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)","title":"Percentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}